Mergers & acquisitions
Shares of Strata Skin Sciences are up more than 12 percent this morning after the company announced it will explore strategic options up to and including a sale of the company in order to enhance stockholder value.
Perrigo is expected to face competition from Swiss food giant Nestle and the private equity owners of German drug firm Stada.
Harpoon’s former CEO also hinted at possible growth at the office, including new hires for engineering and clinical team members.
A look at what three ex-Genentech employees have accomplished at Denali so far.
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting antsy for some good news.
The deal is expected to close in the first quarter of 2018.
Pfizer acquired China/Asia rights for Cresemba, an antifungal drug developed by Swiss pharma Basilea, in a $226M deal.
Esaote S.p.A., an Italian medical imaging company, has been acquired by a group of China investors.
PRESS RELEASES